Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Alternext  >  Theranexus    ALTHX   FR0013286259

THERANEXUS

(ALTHX)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Theranexus : THERANEXUS REPORTS CASH POSITION AS OF JUNE 30, 2019

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/08/2019 | 12:55pm EST

THERANEXUS REPORTS CASH POSITION AS OF JUNE 30, 2019

Lyon, July 8, 2019 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and a pioneer in the development of drug candidates modulating the interaction between neurons and glial cells, today announces its cash position as of June 30, 2019.

Total available funds as of June 30, 2019 stood at €10,231,000, compared to €12,446,000 as of March 31, 2019, reflecting effective cost control. This excludes the French Research Tax Credit for 2018 (€1.7m), which is expected to be collected during the second half, and initial payments receivable under the Neurolead project.

Next financial publication:

September 26, 2019 (before market opening): H1 2019 financial results

ABOUT THERANEXUS
 
Theranexus is a clinical-stage biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA) in 2013. It develops drug candidates for the treatment of nervous system diseases. Theranexus identified the key role played by non-neuronal cells (also known as “glial cells”) in the body's response to psychotropic drugs (which target the neurons). The company is a pioneer in the design and development of drug candidates affecting the interaction between neurons and glial cells. Theranexus has 3 ongoing clinical development programs: THN 102, currently undergoing Phase II clinical trials, aimed at treating daytime sleepiness in Parkinson's disease patients, THN 201 undergoing Phase Ib trials, designed to treat cognitive disorders in patients with Alzheimer's disease, and THN 101, undergoing Phase Ia trials in patients with neuropathic pain. The unique, patented technology used by Theranexus is designed to improve the efficacy of psychotropic drugs already approved and on the market, by combining them with a glial cell modulator. This strategy of combining its innovations with registered drugs means Theranexus can significantly reduce development time and costs and considerably increase the chance of its drugs reaching the market.
The proprietary, adaptable Theranexus platform can generate different proprietary drug candidates offering high added-value for multiple indications.
Theranexus is listed on the Euronext Growth market in Paris (FR0013286259- ALTHX).
More information at: www.theranexus.com

 

 

   
 
Contacts

THERANEXUS
Thierry Lambert

Chief Financial Officer
investisseurs@theranexus.fr
 
 
 
FP2COM
Florence Portejoie

Media Relations
+ 33 (0)6 07 76 82 83
fportejoie@fp2com.fr
 ACTUS finance & communication
 Caroline Lesage / Théo Martin

 Investor Relations
 +33 (0)1 53 67 36 79 / +33 (0)1 53 67 36 75
 theranexus@actus.fr
 

 

 


Regulated information
Inside Information:
- other releases
Full and original press release in PDF:
https://www.actusnews.com/documents_communiques/ACTUS-0-59276-theranexus_pr_cash-position-vdef-en-rev.pdf
Receive by email the next press releases of the company by registering on www.actusnews.com, it′s free


© 2019 ActusNews
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on THERANEXUS
01/21THERANEXUS : Publie son agenda financier 2020
AQ
01/20THERANEXUS : Theranexus announces its financial calendar for 2020
AN
01/16THERANEXUS : Announces the clinical results of its phase ib study demonstrating ..
AQ
01/15THERANEXUS : Theranexus announces the clinical results of its phase ib study dem..
AN
2019THERANEXUS : Theranexus and Beyond Batten Disease Foundation (BBDF) announce the..
AN
2019THERANEXUS : Theranexus reports cash position as of september 30, 2019
AN
2019THERANEXUS : 3rd quarter earnings
CO
2019THERANEXUS : Theranexus announces its first half 2019 results
AN
2019THERANEXUS : A new milestone reached for theranexus: inclusion of last patient i..
AN
2019THERANEXUS : Theranexus announces inclusion of last subject in its phase ib tria..
AN
More news
Financials (EUR)
Sales 2019 0,45 M
EBIT 2019 -9,40 M
Net income 2019 -8,15 M
Finance 2019 0,50 M
Yield 2019 -
P/E ratio 2019 -1,66x
P/E ratio 2020 -1,19x
EV / Sales2019 21,0x
EV / Sales2020 0,53x
Capitalization 9,96 M
Chart THERANEXUS
Duration : Period :
Theranexus Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends THERANEXUS
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Average target price 14,90  €
Last Close Price 2,75  €
Spread / Highest target 511%
Spread / Average Target 442%
Spread / Lowest Target 373%
EPS Revisions
Managers
NameTitle
Franck Joseph Louis Mouthon Chairman & Chief Executive Officer
Thierry Bertrand Lambert Chief Financial Officer
Mathieu Bernard Mari Charveriat Deputy CEO, Director & Chief Scientific Officer
Werner Rein Chief Medical Officer
Dominique Costantini Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
THERANEXUS-9.54%11
GILEAD SCIENCES-1.60%79 894
VERTEX PHARMACEUTICALS4.62%58 903
REGENERON PHARMACEUTICALS-5.03%37 747
WUXI APPTEC CO., LTD.3.98%22 678
GENMAB3.58%14 734